CYP3A4 and infection: TAC has a narrow therapeutic window (~5–10 ng/mL), exhibits high inter- and intrapatient pharmacokinetic variability from absorption and CYP3A metabolism, and therefore requires intensive therapeutic drug monitoring; excursions above and below target are linked to nephrotoxicity or infection risk and rejection, respectively.